The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XII.c

Pericardial effusion (w/wo tamponade)

Publications

Vittorio A, Sharma R, Siejka D, Bhattarai K, Hardikar A

Recurrent Pericardial Effusion While Receiving Nivolumab for Metastatic Lung Adenocarcinoma: Case Report and Review of the Literature.

Clinical lung cancer 2018 09;19;e717-e720 — 2018 09 — e717-e720

de Almeida DVP, Gomes JR, Haddad FJ, Buzaid AC

Immune-mediated Pericarditis With Pericardial Tamponade During Nivolumab Therapy.

Journal of immunotherapy (Hagerstown, Md. : 1997) 2018 09;41;329-331 — 2018 09 — 329-331

Kushnir I, Wolf I

Nivolumab-Induced Pericardial Tamponade: A Case Report and Discussion.

Cardiology 2017;136;49-51 — 2017 — 49-51

Nesfeder J, Elsensohn AN, Thind M, Lennon J, Domsky S

Pericardial effusion with tamponade physiology induced by nivolumab.

International journal of cardiology 2016 Nov 01;222;613-614 — 2016 Nov 01 — 613-614